T3分类子宫内膜癌前哨淋巴结活检的应用趋势
基于美国SEER数据库2010至2018年7004例T3子宫内膜癌患者的回顾性队列研究显示,前哨淋巴结活检使用率从0.4%升至12.9%(P<0.001),多因素分析中2016-2018年较2010-2012年调整比值比为10.1(95%CI 6.30-16.2)。前哨淋巴结活检组与淋巴结清扫组3年总生存率分别为66.3%和64.7%(HR 0.85,95%CI 0.69-1.05),在年轻、年老、子宫内膜样、非子宫内膜样、T3a、T3b及N0亚组中观察到相似关联。
要点
- T3子宫内膜癌前哨淋巴结活检使用率从2010年0.4%升至2018年12.9%。
- 前哨淋巴结活检组较淋巴结清扫组T3b病变调整比值比为0.69(95%CI 0.51-0.94)。
- 两组3年总生存率66.3%对64.7%,HR 0.85(95%CI 0.69-1.05)。
核心结论
- 美国T3子宫内膜癌前哨淋巴结活检的使用率正在增加。
研究设计与样本
- 基于美国国家癌症研究所监测、流行病学和最终结果计划的回顾性队列研究,纳入2010至2018年接受初次手术的7004例T3子宫内膜癌女性。
主要发现
- 淋巴结评估方式包括淋巴结清扫(n=5276,75.3%)、前哨淋巴结活检(n=287,4.1%)和未评估(n=1441,20.6%)。
- 前哨淋巴结活检使用率从2010年0.4%升至2018年12.9%(P<0.001),多因素分析中该关联保持独立:与2010-2012年相比,2013-2015年调整比值比为2.63(95%CI 1.57-4.42),2016-2018年为10.1(95%CI 6.30-16.2)。
- 与淋巴结清扫组相比,前哨淋巴结活检组较少有T3b病变(调整比值比0.69,95%CI 0.51-0.94),但术后化疗和放疗相似(均P>0.05)。
- 加权模型中,前哨淋巴结活检组3年总生存率为66.3%,淋巴结清扫组为64.7%(风险比0.85,95%CI 0.69-1.05)。
- 在年轻、年老、子宫内膜样、非子宫内膜样、T3a、T3b和N0亚组中观察到相似关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The current clinical practice guidelines for endometrial cancer specify sentinel lymph node (SLN) biopsy to be performed in apparent uterine-confined disease. However, a recent population-based analysis found that the utilization of SLN biopsy is increasing in extra-uterine disease such as T2 classification. The objective of this study was to examine trends and outcomes related to SLN biopsy for endometrial cancer with T3 classification, another extra-uterine disease. METHODS: A population-based retrospective cohort study was conducted to examine 7004 women with T3 endometrial cancer who underwent primary surgery between 2010 and 2018, identified in the National Cancer Institute's Surveillance, Epidemiology, and End Results Program. Trends and characteristics related to SLN biopsy were assessed by multinomial regression analysis, and inverse probability of treatment weighting propensity score was used to assess overall survival related to SLN biopsy. RESULTS: Nodal evaluation type included lymphadenectomy (n = 5276, 75.3%), SLN biopsy (n = 287, 4.1%), and none (n = 1441, 20.6%). The utilization of SLN biopsy increased from 0.4% to 12.9% between 2010 and 2018 (P < 0.001) that this association remained independent in multivariable analysis (adjusted-odds ratio compared to 2010-2012, 2.63 [95% confidence interval 1.57-4.42] for 2013-2015 and 10.1 [95% confidence interval 6.30-16.2] for 2016-2018). When compared to the lymphadenectomy group, the SLN biopsy group was less likely to have T3b disease (adjusted-odds ratio 0.69, 95% confidence interval 0.51-0.94) but had similar postoperative chemotherapy and radiotherapy (both, P > 0.05). In a weighted model, the 3-year overall survival rate was 66.3% for the SLN biopsy group and 64.7% for the lymphadenectomy group (hazard ratio 0.85, 95% confidence interval 0.69-1.05). Similar association was observed in subcohorts for young, old, endometrioid, non-endometrioid, T3a, T3b, and N0 cases. CONCLUSION: Utilization of SLN biopsy in T3 endometrial cancer is increasing in the United States.
引用
- Matsuo K, Klar M, Khetan VU, et al. Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification. Gynecol Oncol. 2022. PMID: 35272876. doi:10.1016/j.ygyno.2022.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。